Introduction
Acute myeloid leukemia (AML) is a malignant disease characterized by proliferation and maturation arrest of myeloid blasts in bone marrow and blood [1, 2] . Genetic or epigenetic abnormalities confer the leukemic clones with unlimited self-renewal and blockage of diff erentiation at the specifi c stage of development [3] . In addition to recurrent structural and numerical chromosomal aberrations [e.g. t(15;17) , Ϫ 5q, Ϫ 7q, ϩ 8], the discovery of mutant genes (e.g. FLT3-ITD , CEBPA and NPM1 ) and dysregulated oncogenes ( ERG and BAALC overexpression) has improved the molecular and prognostic classifi cation of AML [2, 4] .
Over the past few years, a new class of small, non-coding RNAs, named microRNAs (miRNAs), has been demonstrated to be altered in AML [5 -7] . Evolutionarily conserved miRNAs are 18 -24 nucleotides (nt) in length and regulate the expression of target mRNAs post-transcriptionally, either through translational inhibition or destabilization of target mRNAs [8] . Several studies have shown that miR-155 expression is elevated in many solid tumors, lymphomas and acute leukemias [9 -12] . miR-196b has been reported to be up-regulated in patients with AML with t(11q23)/ MLL [13 -15] . Th e up-regulation of miR-15a/16-1 has been observed in patients with AML with retinoic acid treatment [16] . Correspondingly, lower levels of miR-223 and miR-29 have been detected in AML samples [17 -19] . Th ese data support tumor suppressor functions of the down-regulated miRNAs, and provide a rationale for the use of synthetic miRNAs as novel therapeutic options in AML [20 -22] . Despite these advances, additional miRNAs and their functional roles in AML remain essentially unclear and are still a matter of interest.
Peroxiredoxins (Prxs) belong to a family of thiol-specifi c antioxidant proteins that also participate in mammalian cell signal transduction [23 -25] . Th e human Prxs include six isoforms (PrxI to PrxVI), and are classifi ed into three subgroups (2-Cys, atypical 2-Cys and 1-Cys) based on the number and positions of the Cys residues that participate in catalysis [26] . PrxIII belongs to the 2-Cys subgroup, and contains both N-and C-terminal Cys residues [27] . During PrxIII catalysis, there are two active sites where Cys residues are oxidized by peroxide substrates to form disulfi de bonds [28] . Notably, alterations in the protein levels of Prxs have been observed in several types of cancer [3, 29] . PrxIII has been reported to be elevated in the formation and development of hepatocellular carcinomas [30] .
Th e present study aimed to identify the specifi c miRNAs associated with AML. To accomplish this, we applied microarray-based miRNA expression profi ling to characterize the miRNAs that are diff erentially expressed in granulocyte cells of peripheral blood from untreated patients with AML and healthy controls. Several diff erentially expressed miRNAs were selected and tested. Among all the validated miRNAs, we report down-regulated miR-26a-5p and miR-23b-3p expression for patients with AML and demonstrate that the two miRNAs modulate the common target PrxIII gene. Moreover, the down-regulated miR-26a-5p and miR-23b-3p exhibited elevation of PrxIII in AML granulocyte samples and transfected cells. Taken together, our fi ndings demonstrate that down-regulation of miR-26a-5p and miR23b-3p by targeting PrxIII may reveal important insights into the pathogenesis of AML.
Materials and methods

Study population
Th e present study included 24 patients with AML (13 females, 11 males) and 16 age-and gender-matched healthy subjects (eight females, eight males). Th e 24 patients with AML included three with M1 (acute myeloblastic leukemia with minimal maturation), eight with M2 (acute myeloblastic with maturation) and 13 with M4 disease (acute myelomonocytic leukemia). Th e mean age of the patients and control subjects was 41 Ϯ 8 years and 34 Ϯ 6 years, respectively. Th e diagnosis of leukemia was made by morphologic and cytochemical studies of bone marrow smears. All patients were not taking any anti-leukemic therapy at the moment of blood sampling and were newly diagnosed with AML. Th e study was approved by the Ethics Review Committee for Human Studies of the Shandong University School of Medicine. All participants provided written informed consent before any blood sampling.
Cell preparation and RNA extraction
Five-milliliter K 2 EDTA (dipotassium ethylenediaminetetraacetic acid) peripheral blood (PB) samples were collected from patients with AML and healthy individuals in Lymphoprep separation medium (Solarbio, Beijing, China). Blood cells were separated by centrifugation at 2000 rpm for 20 min at 4 ° C. Th e blood samples were then separated into four parts, namely plasma, mononuclear, Lymphoprep and sediment layer (including granulocytes and erythrocytes). For enough cell amounts for miRNA microarray, quantitative polymerase chain reaction (PCR) and Western blotting analysis in this study, we used granulocytes isolated from 5 mL PB to detect miRNA expression and verify the cellular results. Th e sediment layer was treated with red blood cell lysis buff er and was then separated by centrifugation at 2000 rpm for 10 min. Th e isolated leukocytes were washed three times in phosphate buff ered saline (PBS). As shown in Supplementary Figure 1 to be found online at http:// informahealthcare.com/doi/abs/10.3109/10428194.2014. 924115, the percentage of granulocytes (CD11b ϩ CD15 ϩ ) after the isolation procedures was assessed using a FACSCalibur fl ow cytometer (BD Biosciences, San Jose, CA), and was higher than 80%. Total RNA was isolated from granulocytes using TRIzol reagent (Invitrogen, Carlsbad, CA) and was treated with RNase-Free DNase (Promega, Fitchburg, WI), according to the manufacturer ' s instructions.
miRNA profi le
The miRNA microarray profiling was conducted by KangChen Bio-tech (Shanghai, China). miRNA expression profi ling of the granulocyte samples was performed using the miRCURY LNA Array (version 11.0) system (Exiqon Inc., Woburn, MA). RNA samples were labeled using a miRCURY Hy3/Hy5 Power labeling kit (Exiqon Inc.) and hybridized on the miRCURY LNA Array station (version 11.0; Exiqon Inc.) . Scanning was performed with an Axon GenePix 4000B microarray scanner (Molecular Devices, LLC, Sunnyvale, CA). GenePix Pro version 6.0 was used to read the raw data of the images. Th e intensity of the green signal was calculated after background subtraction, and replicated spots in the same image were averaged to obtain the median intensity. Th e median normalization method was used to obtain normalized data (foreground minus background divided by median). Th e median represents the 50th quartile of miRNA intensity, which is Ͼ 50% in all samples after background correction. Th e signifi cance of the results was determined using fold change and t -tests. Th e threshold value for signifi cance used to defi ne up-regulation or downregulation of miRNAs was a fold change Ͼ 2 and p -value Ͻ 0.05. Th e miRNAs selected for investigation in this study were further fi ltered on the basis of expression levels and previously published data.
Detection and quantifi cation of miRNAs by quantitative PCR
To confi rm the fi ndings obtained by miRNA profi ling, real-time quantitative reverse transcription PCR (qRT-PCR) was performed using an ABI 7500 system (Applied Biosystems, Foster City, CA). Th e relative expression level of miRNAs was normalized to that of the internal control human U6 by using the 2 Ϫ Δ Δ Ct cycle threshold method. Th e qPCR mixture contained the following components: 12.5 μ L SYBR Premix Ex TaqII (Takara Bio, Otsu, Japan), 2.0 μ L cDNA, 8.5 μ L H 2 O and 1.0 μ L specifi c miRNA primer (Takara Bio). Th e qPCR reaction cycles were: one cycle of 30 s at 95 ° C, 40 cycles of 5 s at 95 ° C, 34 s at 60 ° C, 30 s at 72 ° C and fi nal extension 10 min at 72 ° C.
′ -UTR luciferase reporter assays
Fluorescent reporter experiments were conducted to confi rm that the PrxIII gene, which was predicted to contain miR-26a-5p and miR-23b-3p binding sites, was indeed the target of these two miRNAs. Th e PrxIII 3 ′ -untranslated region (UTR) luciferase reporter construct was made by amplifying the human PrxIII mRNA 3 ′ -UTR sequence and cloning it to the 3 ′ end of a fi refl y luciferase reporter gene in the pmirGLO dual luciferase vector (Promega). Site-directed mutagenesis of a miR-26a-5p or miR-23b-3p target site of PrxIII mRNA was performed using a site-directed gene mutagenesis kit (Beyotime, Beijing, China) using the pmirGLO-PrxIII 3 ′ -UTR plasmid as a template. Mutagenesis primers for a miR-26-a-5p target site of PrxIII were 5 ′ -GTG CGG ATC GTA TTA TTT TAA AAA GTG G-3 ′ (forward) and 5 ′ -GAT TGA CGC AAG GCT AAG AAA GAA G-3 ′ (reverse). Mutagenesis primers for a miR-23b-3p target site of PrxIII were 5 ′ -GCC TTG CGT CAA TCT TTT CAT CTT G-3 ′ (forward) and 5 ′ -GAT CCG CAC TTG CTT CAA TCA CAT AAA C-3 ′ (reverse). HEK293 cells were co-transfected with 10 ng of luciferase reporter plasmid, and miR-26a-5p and miR-23b-3p (fi nal concentration, 5 pM) using Lipofectamine 2000 (Invitrogen), according to the manufacturer ' s instructions. Luciferase activity was measured using the Dual-Luciferase Reporter Assay system (Promega).
Cell culture, transfection and Western blotting analysis
HEK293 and K562 cell lines were maintained in Dulbecco ' s modifi ed Eagle ' s medium (DMEM) and Iscove ' s modifi ed Dulbecco ' s medium with 10% fetal bovine serum (FBS) plus penicillin and streptomycin in a humidifi ed incubator at 37 ° C with 5% CO 2 . HEK293 or K562 cells were transfected the following day using Lipofectamine 2000 (Invitrogen) according to the manufacturer ' s instructions. For overexpression of miRNA, 120 pmol of miR-26a-5p mimic, miR-23-b-3p mimic or negative control mock-miRNA (GenePharma, Beijing, China) was used. For knockdown of miRNA, 100 pmol of miR-26a-5p inhibitor, miR-23b-3p inhibitor or negative control miRNA inhibitor (GenePharma) was used. Cells were harvested 72 h after transfection. For siRNA-mediated knockdown of PrxIII , cells were transfected with 100 pmol of small interfering RNA (siRNA) duplexes (5 ′ -GUG GCA GAG UGA CUU AAC UUT T-3 ′ ) or negative control siRNA duplexes (5 ′ -UUC UCC GAA CGU GUC ACG UTT-3 ′ ) (GenePharma). Analysis was performed after an additional 48 h. Plasmid methods for generating expression constructs of human PrxIII (pcDNA3.1/Myc-HisA-PrxIII) were conducted as previously described [25] .
Antibodies against anti-PrxIII (Abcam, Cambridge, UK), anti-actin (Santa Cruz Biotechnology, Dallas, TX) and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology) were purchased. Th e protein samples prepared from cell cultures were quantifi ed using the Bradford assay, subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto polyvinylidene fl uoride (PVDF) membranes (GE Healthcare, Fairfi eld, CT) for 1 h at 100 V using a standard transfer solution. Th e membranes were then incubated overnight at 4 ° C with the appropriate primary antibody at a 1:1000 dilution, followed by incubation with anti-goat or anti-mouse immunoglobulin G (IgG)-conjugated horseradish peroxidase at a 1:1000 dilution. Th e proteins were visualized by chemiluminescence using an enhanced chemiluminescence (ECL) kit (Th ermo Fisher Scientifi c, Waltham, MA).
Cell diff erentiation assay and determination of cellular ROS by fl ow cytometry
Human K562 is a human leukemia cell line used as model of hematopoietic diff erentiation. K562 cells induced by phorbol myristate acetate (PMA) (Sigma-Aldrich, St. Louis, MO) were stained with anti-human CD11b phycoerythrin (PE) (eBioscience, San Diego, CA) in accordance with the manufacturer ' s instructions. Diff erentiation was analyzed by quantifying the CD11b-positive cell population by fl ow cytometry using the FACSCalibur fl ow cytometer (BD Biosciences). To measure cellular reactive oxygen species (ROS) levels, the cells were incubated with 2 ′ ,7 ′ -dichlorofl uorescein-diacetate (DCFH-DA) (Beyotime) in the dark for 15 min at 37 ° C. After washing, the cells were analyzed by fl ow cytometry, which was performed using the FACSCalibur fl ow cytometer (BD Biosciences). Data were analyzed using the FCSExpress V3 program (DeNovo Software, Los Angeles, CA).
Statistical analysis
All continuous variables are expressed as mean Ϯ standard deviation (SD), unless stated otherwise. Categorical variables were compared using the χ 2 test, and continuous variables were compared using Student ' s t -test. All tests were performed using a two-sided signifi cance level, and p Ͻ 0.05 was considered statistically signifi cant ( * p Ͻ 0.05, * * p Ͻ 0.01 and * * * p Ͻ 0.001). GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) was used for all statistical analyses. All images of Western blotting are representative of at least three independent experiments. qRT-PCR was performed in triplicate and repeated three times.
Results
miRNA profi les in patients with AML versus healthy subjects
To identify aberrantly expressed miRNAs in AML, a miRNA expression assay was performed in granulocytes from four untreated patients with AML and four healthy donors using the miRCURY LNA Array (version 11.0) system. Th e levels of miRNAs diff ered signifi cantly between patients and healthy controls ( Figure 1 ). Of 1700 miRNAs detected on the microarray, 34 miRNAs were found to be diff erentially expressed in patients with AML compared with controls. Quantifi cation revealed that multiple miRNAs were signifi cantly diff erentially expressed in patients compared with healthy controls. According to their known and postulated functions, fi ve miRNAs were selected and further tested. Two of these miRNAs were up-regulated in patients with AML: miR-296-3p and miR-99b-5p. Th ree miRNAs were down-regulated: miR-150-5p, miR-26a-5p and miR-23b-3p. Th e miRNA names, fold changes and p-values are presented in Table I .
Quantitative reverse-transcription polymerase chain reaction validation of profi ling data
To confi rm the fi ndings of the miRNA profi le, the expression of these fi ve diff erentially regulated miRNAs was measured using qRT-PCR. Th e relative expression of each miRNA in patients with AML compared with healthy controls is shown in Figure 2 . Th e results demonstrated a 0.21-fold decrease of miR-26a-5p ( p Ͻ 0.01) and a 0.53-fold decrease of miR23b-3p ( p Ͻ 0.05) in patients with AML. miR-26a-5p and miR-23b-3p are of particular interest among all the validated miRNAs. miR-26a-5p has been reported to inhibit monocytic miR-26a-5p and miR-23b-3p up-regulate PrxIII 463 miR-23b-3p regulate the same target gene: PrxIII , potentially contributing to impaired self-renewal and diff erentiation of hematopoietic stem cells (HSCs) in leukemogenesis.
Independent validation of miRNA expression
To further verify the decreased miR-26a-5p and miR-23b-3p in patients with AML, we studied a second set of granulocyte samples from 20 patients with AML and 12 healthy controls.
diff erentiation of AML cells [31] . In the present study, we chose to use granulocytes isolated from 5 mL PB for suffi cient amounts of cells, and miR-26a-5p/miR-23b-3p were signifi cantly decreased in AML as shown in the distinct granulocyte-based miRNA expression pattern. Most importantly, computational analysis from several widely used mammalian target prediction programs, including miRBase, TargetScan, miRanda, and PicTar, indicated that both miR-26a-5p and Figure 1 . Heat map of miRNA microarray expression data in granulocytes of peripheral blood from patients with AML ( n ϭ 4) and healthy controls ( n ϭ 4). Th e expression of miRNA is hierarchically clustered on the y -axis, and AML granulocyte samples or healthy control granulocyte samples are hierarchically clustered on the x -axis. Legend on the right indicates miRNA represented in the corresponding row. Relative miRNA expression is depicted according to the color scale shown on the right. Red indicates up-regulation, green down-regulation. Numbers A1, A2, A3, A4 indicate AML patient samples; numbers B1, B2, B3, B4 indicate healthy control samples.
As shown in Figure 3 , the two miRNAs were signifi cantly decreased in patients compared with healthy controls. Our results showed a 0.14-fold decrease of miR-26a-5p and a 0.18-fold decrease of miR-23b-3p in patients with AML compared with healthy control subjects (both p Ͻ 0.0001).
PrxIII is a direct target of both miR-26a-5p and miR-23b-3p
To identify the direct target genes of miR-26a-5p or miR23b-3p, we combined several widely used mammalian target prediction programs, including miRBase, miRanda, TargetScan and PicTar [32 -34] . Among all the putative genes, PrxIII is of particular interest because it is present in the lists of candidate genes targeted by both miR-26b-5p and miR-23b-3p. Th us, we investigated whether miR-26a-5p and miR-23b-3p target PrxIII for expression regulation. To this end, Western blot and qRT-PCR were performed to demonstrate the eff ects of miR-26a-5p and miR-23b-3p on the regulation of PrxIII expression in vitro . HEK293 cells were treated with inhibitors specifi c for miR-26a-5p, miR-23b-3p or miR-26-a-5p ϩ miR-23b-3p or with control microRNAs [ Figure 4 We further determined whether miR-26a-5p and miR-23-b-3p could directly alter the expression of PrxIII . Th e PrxIIIencoded mRNA contains a 3 ′ -UTR element that is partially complementary to miR-26a-5p and miR-23b-3p [ Figure 4 (E)], indicating that the miRNAs might directly target the corresponding sites. A fragment of the 3 ′ -UTR of PrxIII mRNA containing the wild-type or mutated putative miR-26a-5p or miR-23b-3p corresponding binding sequence was cloned into a luciferase reporter construct, respectively [ Figure 4 (E)]. Th e luciferase reporter assay in HEK293 cells showed that the luciferase activity was decreased by 31% when co-transfected with miR-26a-5p and its corresponding pmirGLO-PrxIII -wt [Figure 4(F) , open bars] and 43% when co-transfected with miR-23b-3p and its corresponding pmirGLO-PrxIII -wt [ Figure 4 (F), open bars], whereas no signifi cant reduction in luciferase activity was observed when the cells were transfected with miR-mock. Th e construct pmirGLO-PrxIII -mut was then used to repeat the luciferase assay experiments in HEK293 cells, which showed that mutating the seed region for miR-26a-5p or miR-23b-3p in the pmirGLO-PrxIII -wt plasmid completely abrogated its regulatory activity [ Figure  4 (F), fi lled bars]. Th e results demonstrated that miR-26a-5p or miR-23b-3p might suppress PrxIII expression through corresponding binding sites at the 3 ′ -UTR of PrxIII .
Detection of PrxIII in K562 cells and granulocytes from patients with AML
To study the signifi cance of the miR-26a-5p-and miR-23-b-3p-dependent suppression of PrxIII expression, a human myeloid leukemia cell line (K562) was treated with inhibitors and mimics specifi c for miR-26a-5p and miR-23b-3p. As shown in Figures 5(A) and 5(B) , the mRNA and protein levels of the PrxIII gene increased signifi cantly compared with the negative controls when inhibitors of miR-26a-5p or miR-23b-3p were transfected into K562 cells. Correspondingly, mimics of miR-26a-5p or miR-23b-3p decreased PrxIII mRNA and protein levels [ Figures 5(A) and 5(B) ]. In further analysis of PrxIII in granulocytes from untreated patients with AML, we found that the protein levels of PrxIII were signifi cantly higher in 11 patients with AML compared with six control subjects [Figures 5(C) and 5(D)]. Our fi ndings suggest that elevated PrxIII protein levels were regulated by decreased miR-26a-5p and miR-23b-3p in patients with miR-26a-5p and miR-23b-3p up-regulate PrxIII 465 AML compared with control subjects. In addition, the increase in PrxIII expression caused by inhibitor specifi c for miR-26a-5p or miR-23b-3p was off set in siPrxIII ϩ miR26a-5p/miR-23b-3p inhibitor cells, demonstrating that the elevated PrxIII was indeed mediated by the down-regulation of miR-26a-5p or miR-23b-3p [ Figure 5 (E)].
Determination of cellular ROS by fl ow cytometry
Next, we investigated the contribution of the miR-26a-5p/ miR-23b-3p-PrxIII regulatory pathway to the ROS status in HEK293 and K562 cell lines. ROS are involved in regulating the balance between self-renewal and diff erentiation of HSCs. Th e increased ROS levels might act as an intracellular miR-26a-5p and miR-23b-3p up-regulate PrxIII 467 dye) and then analyzed using fl ow cytometry. Importantly, the transfection of miR-26a-5p inhibitor or miR-23b-3p inhibitor led to a signifi cant decrease in ROS production in both HEK293 cells and K562 cells [ Figure 6 (A), red and blue lines]. Quantitative summary of three replicated experiments indicated that ROS production was reduced signifi cantly in miR-26a-5p/miR-23b-3p down-regulated cells compared trigger for HSC diff erentiation to myeloid lineage fates in hematopoietic systems [35, 36] . Th erefore, we predicted that overexpression of PrxIII caused by down-regulation of miR26a-5p and miR-23b-3p would have similar eff ects. To this end, HEK293 and K562 cells were fi rst treated with control miRNA and miR-26a-5p/miR-23b-3p inhibitor. Next, cells were pre-labeled with DCFH-DA (a free radical-recognizing Figure 6 . miR-26a-5p and miR-23b-3p decrease levels of ROS. (A) HEK293 and K562 cells transfected with control, miR-mock, miR-26a-5p inhibitor and miR-23b-3p inhibitor were labeled with DCFH-DA and analyzed by fl ow cytometry. A representative histogram (green, red and blue lines indicate ROS production in transfection of miR-mock, miR-26a-5p inhibitor and miR-23b-3p inhibitor, respectively) is shown. (B) DCFH-DA fl uorescence measurements of cellular ROS levels in transfection of miR-mock, miR-26a-5p inhibitor and miR-23b-3p inhibitor in HEK293 or K562 cells. Columns, mean; bars, Ϯ SD; * p Ͻ 0.05, * * p Ͻ 0.01. Compiled data were produced from three independent experiments. (C) HEK293 and K562 cells transfected with control, miR-mock, miR-26a-5p mimic and miR-23b-3p mimic were labeled with DCFH-DA and analyzed by fl ow cytometry. A representative histogram (green, red and blue lines indicate ROS production in transfection of miR-mock, miR-26a-5p mimic and miR-23b-3p mimic, respectively) is shown. (D) DCFH-DA fl uorescence measurements of cellular ROS levels in transfection of miR-mock, miR-26a-5p mimic and miR-23b-3p mimic in HEK293 or K562 cells. Columns, mean; bars, Ϯ SD; * p Ͻ 0.05, * * p Ͻ 0.01, * * * p Ͻ 0.01. Compiled data were produced from three independent experiments. (E) HEK293 and K562 cells transfected with control, miR-mock, miR-26a-5p inhibitor ϩ siPrxIII and miR-23b-3p inhibitor ϩ siPrxIII were labeled with DCFH-DA and analyzed by fl ow cytometry. A representative histogram (green, red and blue lines indicate ROS production in transfection of miR-mock, miR-26a-5p/miR-23b-3p inhibitor and miR-26a-5p/miR-23b-3p inhibitor ϩ siPrxIII, respectively) is shown. (F) DCFH-DA fl uorescence measurements of cellular ROS levels in transfection of miR-mock, miR-26a-5p/miR-23b-3p inhibitor and miR-26a-5p/miR-23b-3p inhibitor ϩ siPrxIII in HEK293 cells. Columns, mean; bars, Ϯ SD; * p Ͻ 0.05. Compiled data were produced from three independent experiments.
replicated experiments indicated that ROS production was reduced signifi cantly in anti-miR-26a-5p (anti-miR-23b-3p) cells compared with negative control cells, whereas in miR-26a-5p/miR-23b-3p inhibitor ϩ siPrxIII cells, ROS production was restored to the level in negative control cells [Figure 6(F) ].
PrxIII responsible for ROS production and K562 cell diff erentiation
Last, we investigated the contribution made by the PrxIII/ ROS regulatory pathway to AML cell diff erentiation. Th e K562 cell line has been used as a model for the study of AML cell diff erentiation, which could be achieved by exposure to PMA [37] . As shown in Figure 7 (A), Western blotting analysis with negative control cells [ Figure 6 (B)]. ROS induction by miR-26a-5p or miR-23b-3p mimic was also measured. As expected, the results showed that ROS levels were signifi cantly higher in miR-26a-5p/miR-23b-3p up-regulated cells compared with control cells [Figures 6(C) and 6(D) ].
To determine whether the diff erence was due to the PrxIII expression, ROS production was measured in miR-26a-5p/ miR-23b-3p inhibitor ϩ siPrxIII cells. As shown in Figure  6 (E), the decrease in ROS production caused by miR-26a-5p/ miR-23b-3p inhibitor (red line) was off set in miR-26a-5p/ miR-23b-3p inhibitor ϩ siPrxIII (blue line), demonstrating that the reduction in ROS production of the transfection of miR-26a-5p/miR-23b-3p inhibitor was indeed mediated by the up-regulation of PrxIII. Quantitative summary of three miR-26a-5p and miR-23b-3p up-regulate PrxIII 469
PrxIII is an important regulator of cellular ROS. Elevated PrxIII induced decreased levels of cellular ROS. Although PrxIII is widely believed to function as a scavenger of H 2 O 2 and to protect against ROS-induced damage, other functions have been proposed, such as the regulation of cellular signal transduction [45, 46] . We have shown that miR-26a-5p/miR23b-3p-inhibited cells are able to scavenge excess ROS. Th e K562 cell line has been used as a model for the study of diff erentiation, which could be achieved by exposure to PMA [37] . PMA-diff erentiated K562 cells were conducted with silencing/overexpression of PrxIII to clarify its function during diff erentiation. Our data indicated that PrxIII is responsible for ROS production and AML cell diff erentiation. Although the majority of studies have focused on the damaging eff ects of ROS, emerging evidence now suggests that the ROS signal plays a critical role in regulating the balance between self-renewal and diff erentiation of HSCs. High ROS levels could actually act as an intracellular trigger for HSC diff erentiation to myeloid lineage fate [35] . For example, a high ROS state enhances proliferation and self-renewal of HSCs [47] . It has been found that Drosophila multipotent hematopoietic progenitors maintain a high ROS status and are highly responsive to ROS stimulation [36] . Correspondingly, a decrease in normal cellular ROS levels had negative impacts on the diff erentiation potential into mature blood cells [36] . In addition, iron deprivation was shown to promote leukemic cell diff erentiation by resulting in dose-and time-dependent ROS formation [48] .
In the present study, we observed that the accumulation of PrxIII caused by decreased miR-26a-5p and miR-23b-3p leads to a considerable decrease in ROS production. In support of these fi ndings, alternations in the protein levels of Prxs were recently found in various types of cancer. PrxI and PrxII have been found to be elevated in several types of cancer cells and tissues such as oral, esophageal, pancreatic, follicular thyroid, breast and lung cancers [29] . PrxII was found to be signifi cantly increased in AML cells by using two-dimensional electrophoresis coupled with mass spectrometry [49] . Notably, PrxII was also demonstrated as an inhibitor of myeloid cell growth by reducing ROS levels in AML [50] . Also PrxIII has been reported to be elevated in the formation and development of hepatocellular carcinomas [30] . In light of these data, the down-regulation of miR26a-5p and miR-23b-3p is expected to cause the accumulation of PrxIII, and thus enhance its ROS scavenging capacity. It is possible that decreased ROS levels as a consequence of miR-26a-5p/miR-23b-3p defi ciency might not be high enough to sustain normal hematopoietic stem cell proliferation and impair normal hematopoiesis.
In conclusion, the present study demonstrated a miRNA expression profi le in granulocytes for AML and that both miR-26a-5p and miR-23b-3p directly target the PrxIII gene. It would be interesting to further investigate the eff ects of miR-26a-5p and miR-23b-3p and the resulting stability of PrxIII in stem cells and/or animal models. However, a large number of miRNAs might be involved in AML and leukemogenesis. In addition, our fi ndings based on Chinese patients with AML may not be generalized to other populations and a large number of specifi c miRNAs might be revealed that the expression of PrxIII was signifi cantly repressed during diff erentiation of K562 cells induced by PMA. ROS has been reported as a key factor for PMA-induced diff erentiation [38] . PMA-diff erentiated K562 cells were conducted with silencing/overexpression of PrxIII , to clarify its function during diff erentiation by detection of the CD11b diff erentiation marker. To this end, K562 cells were treated with siRNA specifi c for PrxIII and with the pcDNA3.1A-PrxIII plasmid [Figures 7(B) and 7(C)]. Next, cells were pre-labeled with DCFH-DA and anti-human CD11b and then analyzed using fl ow cytometry, respectively. Importantly, silencing of PrxIII led to a signifi cant increase in ROS production and vice versa [Figure 7(D) , red and blue lines]. Quantitative summary of three replicated experiments indicated that ROS production was increased 2.6-fold in PrxIII -silenced cells compared with negative control cells, whereas in pcDNA3.1A-PrxIII transfected cells, ROS production was reduced 0.7-fold compared with negative control cells [Figure 7(E) ]. As shown in Figures 7(F) and 7(G), our data showed that the percentage of CD11b ϩ was 27.6 Ϯ 3.6% induced by PMA, 78.2 Ϯ 9.9% with PMA induction and silencing of PrxIII , and 1.5 Ϯ 0.2% with PMA induction and transfection with pcDNA3.1A-PrxIII plasmid. Collectively, these results support the conclusion that the level of PrxIII was responsible for ROS production and AML cell diff erentiation.
Discussion
Leukemogenesis is an evolutionary process that involves multiple independent genetic and epigenetic events. Many diff erent causes may alter normal leukemogenesis, including aberrant behavior of chromosomal abnormalities, dysregulation of certain oncogenes and altered intracellular pathways. Over the past few years, emerging evidence suggests that aberrantly expressed miRNAs play a signifi cant role in leukemogenesis [5, 39] . miRNAs involved in leukemogenesis are divided into two types: oncogenic miRNA (oncomir), such as miR-155, and tumor-suppressive miRNA, such as miR-29b [2, 5, 40] .
For enough cell amounts for miRNA microarray, quantitative PCR and Western blotting analysis in the present study, we used granulocytes isolated from 5 mL PB to detect miRNA expression and verify the cellular results. We demonstrated a distinct granulocyte-based miRNA expression pattern in patients with AML compared with healthy controls, including 20 miRNAs that were up-regulated and 14 miRNAs that were down-regulated. Particularly, we observed that two miRNAs, miR-26a-5p and miR-23b-3p, were signifi cantly decreased in patients with AML. Both miR-26 and miR-23 are functional miRNAs that have been previously studied. miR-26 has been reported in several types of tumor (such as bladder and breast cancers), and may exhibit tumor-suppressive activities during tumorigenesis [40 -42] . miR-23 has also been reported to be dysregulated in renal, breast and prostate cancers [43, 44] . Our results indicate that both miR-26a-5p and miR-23b-3p are dysregulated in AML and that they directly target the PrxIII gene.
